2 results
Approved WMORecruiting
to study the anti-tumor effect of cannabis oil (THC10% / CBD5%) in untreatable advanced HCC patients based on imaging using RECIST and modified RECIST (mRECIST) criteria
Approved WMORecruiting
Part A: To determine the recommended phase 2 dose and schedule of the RMC-4630 and LY3214996 combination in patients with KRASm advanced CRC, NSCLC and PDAC.Part B: To determine the safety and tolerability of RMC-4630 in combination with LY3214996…